Type 1 Diabetes Trial, Recruiting NCT06694558 Sponsor: The Cleveland Clinic Condition: Type 1 Diabetes
Back to Type 1 Diabetes

Type 1 Diabetes Trial, Recruiting

NCT06694558
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are an adult (age 18–65) who has been diagnosed with Type 1 diabetes
  • You use insulin injections or an insulin pump to manage your diabetes
  • You currently use a continuous glucose monitor (CGM)
  • If you have kidney disease: You have been told your kidneys are working at a mildly reduced level (eGFR between 60–90), AND you have a moderate amount of protein in your urine (confirm with trial site)
  • If you do not have kidney disease: Your kidneys are working normally (eGFR above 90) AND you do not have extra protein in your urine (confirm with trial site)
  • Your blood sugar control levels (based on CGM readings and HbA1c results) fall within one of two specific ranges that the trial team will assess

Who may not be able to join:

  • Your hemoglobin (a measure of red blood cells) is below 9 (confirm with trial site)
  • You have used certain diabetes or blood sugar medications (GLP-1 agonists, DPP4 inhibitors, or SGLT-2 inhibitors) in the last 30 days
  • You are pregnant or planning to become pregnant
  • You are currently taking steroid medications
  • You have been diagnosed with cancer, or have an autoimmune or immune-suppressing condition
  • You have reported heavy alcohol use or recreational drug use
  • You have any other condition that your doctor believes could affect your safety or certain immune cells in your blood (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 19 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Rong M Zhang, MD, The Cleveland Clinic

Phone: 216-445-8354

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 March 2025
Est. completion
30 December 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Number of subjects with proinflammatory monocytes by flow cytometry, higher ER stress, and cytokine levels after monocyte exposure to hyperglycemia compared to euglycemia for 6 hours.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov